🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
10.01
-0.18 (-1.77%)
Nov 19, 2026, 4:00 PM EST - Market closed

Corvus Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
12.899.258.166.87.519.28
Research & Development
54.8633.7219.3916.5324.4729.12
Operating Expenses
67.7542.9727.5523.3331.9838.4
Operating Income
-67.75-42.97-27.55-23.33-31.98-38.4
Interest & Investment Income
6.342.511.821.580.65-
Earnings From Equity Investments
-2.91-1.96-3.2-5.28-10.01-4.83
Other Non Operating Income (Expenses)
-27.14-33.38---0.02
EBT Excluding Unusual Items
-64.32-15.28-62.3-27.03-41.33-43.24
Gain (Loss) on Sale of Assets
--0.01-0.02-
Pretax Income
-64.32-15.28-62.29-27.03-41.31-43.24
Net Income
-64.32-15.28-62.29-27.03-41.31-43.24
Net Income to Common
-64.32-15.28-62.29-27.03-41.31-43.24
Net Income Growth
------
Shares Outstanding (Basic)
897961484742
Shares Outstanding (Diluted)
898061484742
Shares Change
18.80%30.76%26.99%3.16%11.23%41.98%
EPS (Basic)
-0.72-0.19-1.02-0.56-0.89-1.03
EPS (Diluted)
-0.72-0.53-1.02-0.56-0.89-1.03
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-47.94-32.97-25.42-23.97-27.29-36.72
Free Cash Flow Per Share
-0.54-0.41-0.42-0.50-0.59-0.88
EBITDA
-67.57-42.87-27.46-23.18-31.61-37.94
D&A For EBITDA
0.180.110.090.150.370.46
EBIT
-67.75-42.97-27.55-23.33-31.98-38.4
SEC Filings: 10-K · 10-Q